Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma
Results from CheckMate -76K Demonstrate Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival Data reinforce the benefits of Opdivo in earlier stages of melanoma
Source: finanznachrichten.de